Overactive Bladder
Conditions
Interventions
Treatment group receiving a single injection into the detrusor muscle of 10ml of ADSC solution
Placebo group receiving single injection into the detrusor muscle of 10ml of normal saline
Sponsors
Al Zahraa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients with a clinical diagnosis of PD according to UK Brain Bank Criteria, patients age between 40 and 70 years, have a stable dose of antiparkinsonian drugs 8 weeks before study entry, stage 1 to 3 on modified Hoehn and Yahr scale, patients had an urgency score more or equa than 2 and a total score more or equal than 3 of the OAB symptom score (OABSS)
Exclusion criteria
Exclusion criteria: patients with secondary parkinsonism syndromes, patients with polyuria with a daily urine volume more than 3000 mL, patients taking anticholinergic medications for OAB symptoms, history of benign prostatic hypertrophy, patients with stress urinary incontinence or urinary tract infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change from baseline in OAB symptom score (OABSS) and the overactive bladder questionnaire short form (OAB-q SF) score in patients with Parkinson's disease | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes were the change from baseline in the mean number of micturitions per 24 h, the mean number of urgency episodes per24 h, the mean number of urgency incontinence episodes per 24 h, and the mean number of nocturia episodes per night as recorded on a 3-day bladder diary at baseline and 6 months later. Safety assessments included any reported adverse events | — |
Countries
Asia(except Japan)
Contacts
Public ContactMohamad Moussa
Al Zahraa Hospital Urology
Outcome results
None listed